GlassScriptPhysician profile
David Earl Perry
NPI 1295029528
$8,092.83
in general payments reported to CMS, 2019-2025
41 companies · $831 in 2025
The $831 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,029 · 2020: $731 · 2021: $1,284 · 2022: $1,095 · 2023: $2,066 · 2024: $1,058 · 2025: $831.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,828 · Travel and Lodging: $1,126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,828.25 |
| Travel and Lodging | $1,125.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,360.86 | 2021-2025 | Mitraclip, Merlin@Home, Jot Dx |
| Pfizer INC. | $1,126.94 | 2019-2025 | |
| Amgen INC. | $666.90 | 2019-2025 | Repatha, Repatha, Otezla |
| Actelion Pharmaceuticals US, INC. | $625.55 | 2019-2025 | Uptravi, Opsumit |
| Janssen Pharmaceuticals, INC | $528.16 | 2019-2023 | Xarelto |
| Boston Scientific Corporation | $519.02 | 2019-2024 | Synergy, Watchman Flx |
| Novartis Pharmaceuticals Corporation | $493.00 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $466.86 | 2021-2025 | Verquvo, Winrevair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $438.28 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $259.69 | 2019-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $212.59 | 2019-2023 | Farxiga |
| Lantheus Medical Imaging, INC. | $209.31 | 2019-2023 | Definity |
| Amarin Pharma, INC. | $167.34 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $110.68 | 2020-2025 | Amvuttra |
| United Therapeutics Corporation | $87.79 | 2019-2025 | Tyvaso |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $84.07 | 2023-2024 | Hillrom - Carnation Ambulatory Monitor |
| Bridgebio Pharma, INC. | $79.81 | 2025 | Attruby |
| Heartflow, INC. | $71.15 | 2023-2025 | Ffrct |
| Gilead Sciences, INC. | $68.13 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $62.49 | 2022-2023 | Arcalyst |
| Impulse Dynamics (USA) INC. | $50.40 | 2024 | Optimizer |
| Masimo Corporation | $43.90 | 2022 | |
| Inspire Medical Systems, INC. | $43.39 | 2024-2025 | Inspire |
| Kiniksa Pharmaceuticals International, Plc | $31.86 | 2024 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $23.36 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $22.76 | 2024 | |
| Edwards Lifesciences Corporation | $20.06 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Cvrx, INC. | $19.07 | 2025 | Barostim Neo System |
| Cardinal Health 200 LLC | $18.83 | 2019 | |
| Medtronic, INC. | $18.37 | 2021 | |
| Organon LLC | $17.19 | 2025 | Nexplanon |
| Chiesi USA, INC. | $16.77 | 2019 | |
| Genzyme Corporation | $16.12 | 2021 | |
| Irhythm Technologies, INC. | $15.93 | 2022 | |
| Daiichi Sankyo INC. | $15.91 | 2021 | |
| Esperion Therapeutics, INC. | $14.30 | 2021 | |
| Teleflex LLC | $14.30 | 2024 | Turnpike |
| Analog Devices INC. | $14.02 | 2024 | Sensinel Cpm Wearable |
| Biotronik INC. | $13.15 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.11 | 2023 | Livalo, Seglentis |
| Novo Nordisk INC | $11.41 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Perry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.